NIJBAS
Publications 2025

OPEN ACCESS
ONLINE ISSN: 2992-5797
PRINT ISSN: 2992-6122

NEWPORT INTERNATIONAL JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES (NIJBAS)

Volume 7 Issue 2 Page 102-105, 2026

https://doi.org/10.59298/NIJBAS/2026/7.2.102105

Circumsporozoite Protein Biomarkers: Vaccine-Induced Immunity and Transmission Reduction in Endemic Settings

Mutebi Mark

Department of Pharmacology Kampala International University Uganda
Email: mark.mutebi@studwc.kiu.ac.ug

ABSTRACT

Malaria remained a major global health challenge, particularly in endemic regions, and continues to contribute significantly to morbidity and mortality. The circumsporozoite protein (CSP) was a key biomarker in malaria, playing a critical role in both immune responses and parasite transmission. It emerged as a prominent target in the development of malaria vaccines. This article aimed to provide a comprehensive review of CSP as a biomarker for malaria vaccine development, focusing on its role in vaccine-induced immunity and its potential for transmission reduction in endemic areas. A thorough review of current literature, vaccine trials, and studies related to CSP, vaccine efficacy, and transmission blocking strategies in endemic regions was conducted. CSP-targeted vaccines, especially the RTS,S/AS01 vaccine, have shown promise in inducing protective immunity and reducing transmission. However, challenges such as limited efficacy in high-transmission areas and the need for improved durability of protection remained. CSP-based vaccines were a promising tool in malaria control, but further research is necessary to address current limitations. Future vaccine development should focus on improving vaccine efficacy, particularly in high-transmission areas, and enhancing accessibility and sustainability in endemic regions.

Keywords: Circumsporozoite protein, Malaria vaccine, Transmission reduction, Endemic regions, Vaccine efficacy.

INTRODUCTION

Malaria, a mosquito-borne infectious disease caused by *Plasmodium* species, continues to be a leading cause of morbidity and mortality, particularly in sub-Saharan Africa [1, 2]. The disease remains a major global health burden, exacerbated by the spread of drug-resistant strains and challenges in vaccine development. Recent efforts have focused on developing vaccines that can reduce transmission and provide durable immunity, with the circumsporozoite protein (CSP) being a key target. CSP is an essential protein found on the surface of the *Plasmodium* sporozoite, the life stage of the parasite that infects humans through the bite of infected mosquitoes [3].

CSP has become a significant biomarker in malaria vaccine development due to its ability to elicit immune responses capable of inhibiting parasite invasion [4, 5]. Several CSP-targeted vaccines have been developed, with the RTS,S/AS01 vaccine being the most studied and the first to receive partial approval for use in malaria-endemic areas. While these vaccines have shown encouraging results, their efficacy in reducing malaria transmission, particularly in high-transmission regions, remains a challenge.

This review aims to explore the role of CSP as a biomarker for vaccine-induced immunity and its potential in reducing malaria transmission in endemic areas. It will provide an in-depth analysis of the immunological mechanisms triggered by CSP-targeted vaccines, examine the current state of vaccine development, and evaluate the success of these vaccines in clinical trials and real-world implementation. Furthermore, this article will address the challenges faced in malaria-endemic settings, including issues related to vaccine deployment, accessibility, and

public health infrastructure. The goal of this study is to provide a comprehensive understanding of CSP's role in malaria control and suggest directions for future research and development.

Role of CSP in Malaria Immunity

The circumsporozoite protein (CSP) is a highly conserved surface protein present on the sporozoites of the *Plasmodium* parasite [6]. Its primary role in the parasite's lifecycle is to facilitate the invasion of liver cells upon transmission by an infected mosquito. CSP is composed of a central repeat region that is crucial for its function and interaction with the host immune system [7]. The protein serves as a target for both cellular and humoral immune responses, making it a prime candidate for vaccine development.

Upon infection, the immune system recognizes CSP as a foreign antigen, triggering the production of antibodies and activating T-cells that specifically target the parasite [8]. These immune responses are essential for reducing the parasite load and preventing the development of malaria. CSP-targeted vaccines aim to induce both a strong humoral response, primarily through the production of antibodies, and a cellular response involving T-cells capable of targeting infected liver cells.

The immune system's ability to generate long-lasting immunity to CSP is critical for malaria prevention. Research has demonstrated that individuals who have been exposed to malaria in endemic regions often develop partial immunity over time, primarily through the development of antibodies against CSP [9]. However, the complexity of the immune response to *Plasmodium* makes it challenging to develop a universally effective vaccine, as the immune response may vary based on geographic location, the transmission intensity of the parasite, and the presence of other co-infections.

CSP as a Target for Malaria Vaccines

Malaria vaccines have been a critical component of global efforts to control the disease, and targeting the circumsporozoite protein has proven to be a promising strategy [10]. The RTS,S/AS01 vaccine, developed by GlaxoSmithKline, is the first malaria vaccine to show partial success in clinical trials and has received partial approval from the World Health Organization (WHO) for use in certain malaria-endemic areas. This vaccine contains a recombinant version of CSP fused with the hepatitis B surface antigen, combined with an adjuvant to enhance immune responses.

RTS,S/AS01 has demonstrated moderate efficacy in preventing malaria infection in young children, with protection rates of around 30-40% in large-scale trials [11, 12]. However, its efficacy varies based on transmission intensity and age groups, with the vaccine being more effective in children with prior malaria exposure. Despite its limited efficacy, RTS,S/AS01 has been considered a significant breakthrough in the field of malaria vaccine development.

Other CSP-based vaccine candidates are in development, including those using alternative adjuvants or modified formulations to improve immune responses. A major focus of current research is to increase the durability of immunity, as RTS,S/AS01 offers protection for only a limited time post-vaccination. Moreover, the emergence of novel vaccine platforms, such as mRNA vaccines, presents new opportunities for enhancing CSP-targeted vaccines and optimizing their effectiveness.

Impact of CSP Vaccines on Transmission Reduction

One of the primary goals of malaria vaccines is not only to prevent infection but also to reduce transmission within populations. In this context, CSP-targeted vaccines, including RTS,S/AS01, have shown promising results in reducing malaria transmission [13]. The RTS,S/AS01 vaccine has been shown to reduce the incidence of malaria cases and prevent the transmission of *Plasmodium* from human hosts to mosquitoes.

Clinical trials have demonstrated that the vaccine significantly reduces the number of gametocytes (the sexual form of the parasite) in the blood of vaccinated individuals, which directly impacts the ability of mosquitoes to become infected [14]. This transmission-blocking effect is crucial for reducing the spread of malaria, particularly in high-transmission areas where the parasite load in humans is high.

However, the ability of CSP-based vaccines to reduce transmission varies depending on several factors, including the transmission intensity of the region, the age of the individuals vaccinated, and the presence of co-infections. In areas with high transmission rates, the effectiveness of CSP vaccines in reducing transmission may be limited by the large number of asymptomatic individuals who carry the parasite without exhibiting clinical symptoms [15]. These individuals can still serve as reservoirs for transmission, even if they are protected from clinical disease.

Challenges in Implementing CSP Vaccines in Endemic Settings

While CSP-based vaccines show promise, their implementation in malaria-endemic settings faces several challenges. One of the major obstacles of CSP-based vaccines is the accessibility and affordability of vaccines in low-resource settings [16, 17]. Malaria-endemic regions often face challenges in healthcare infrastructure, including limited

access to vaccines, healthcare workers, and diagnostic tools. Additionally, vaccine hesitancy, driven by misinformation or lack of trust in vaccination programs, can undermine the success of vaccination campaigns.
Another challenge is the diversity of *Plasmodium* species and the genetic variability of the CSP protein [18, 19]. Malaria transmission is not limited to a single *Plasmodium* species, and vaccine efficacy may vary across different species, such as *Plasmodium falciparum* and *Plasmodium vivax*. Moreover, the CSP protein exhibits genetic diversity across different geographic regions, which may impact the vaccine's effectiveness in different populations.

In addition, the limited duration of immunity provided by CSP vaccines, particularly RTS,S/AS01, poses a significant challenge in endemic areas with high transmission rates. Booster doses may be required to maintain immunity, adding complexity to vaccine distribution and cost.

Future Directions and Innovations in CSP Vaccine Development

The future of CSP-based vaccines lies in optimizing current formulations and exploring new vaccine platforms. Advances in vaccine technology, such as mRNA vaccines, offer the potential to enhance vaccine efficacy by allowing for more rapid development and customization to target different *Plasmodium* strains [20, 21]. Additionally, combination vaccines that target multiple stages of the *Plasmodium* lifecycle or that include CSP along with other malaria antigens may provide broader protection.
Research into improving the durability of vaccine-induced immunity is crucial for the long-term success of malaria control efforts. New adjuvants, alternative delivery systems, and innovative vaccine platforms could enhance the immune response and extend the duration of protection.
Collaboration between researchers, governments, and international health organizations will be key to overcoming the logistical, economic, and societal challenges associated with implementing CSP-based vaccines. Ensuring that vaccines are accessible, affordable, and acceptable to communities will be critical in the fight against malaria.

CONCLUSION

CSP-based vaccines, particularly RTS,S/AS01, represent a promising tool in the fight against malaria. These vaccines have demonstrated efficacy in inducing immune responses and reducing transmission in endemic regions. However, challenges such as limited vaccine efficacy, especially in high-transmission areas, and the need for sustained immunity remain significant barriers. Addressing these challenges through innovative research and development is crucial for improving the impact of CSP-targeted vaccines. Future efforts should focus on improving the durability of immunity, optimizing vaccine formulations, and ensuring broad access to vaccines in malaria-endemic regions. In addition, novel approaches, such as combination vaccines and mRNA-based vaccines, hold the potential to further enhance the efficacy of CSP vaccines. To maximize the potential of CSP-based vaccines in malaria control, future research should prioritize improving vaccine efficacy and extending protection duration, particularly in high-transmission settings.

REFERENCES

1. Alum, E.U., Tufail, T., Agu, P.C., Akinloye, D.I., Obaroh, I.O.: Malaria pervasiveness in Sub-Saharan Africa: Overcoming the scuffle. Medicine. 103, e40241 (2024). https://doi.org/10.1097/MD.0000000000040241
2. Alum, E.U., Ugwu, O.P.-C., Egba, S.I., Uti, D.E., Alum, B.N.: Climate Variability and Malaria Transmission: Unraveling the Complex Relationship. INOSR SR. 11, 16–22 (2024). https://doi.org/10.59298/INOSRSR/2024/1.1.21622
3. Swearingen, K.E., Lindner, S.E., Shi, L., Shears, M.J., Harupa, A., Hopp, C.S., Vaughan, A.M., Springer, T.A., Moritz, R.L., Kappe, S.H.I., Sinnis, P.: Interrogating the Plasmodium Sporozoite Surface: Identification of Surface-Exposed Proteins and Demonstration of Glycosylation on CSP and TRAP by Mass Spectrometry-Based Proteomics. PLOS Pathogens. 12, e1005606 (2016). https://doi.org/10.1371/journal.ppat.1005606
4. Ngulube, P.: Humoral Immune Responses to P. falciparum Circumsporozoite Protein (Pfcsp) Induced by the RTS, S Vaccine – Current Update. Infection and Drug Resistance. 16, 2147–2157 (2023). https://doi.org/10.2147/IDR.S401247
5. Mitchell, R.A.: Humoral and Cellular Immune Responses to Pre-Erythrocytic Malaria Vaccination and Impact of Epidemiological Factors. (2024)
6. Swearingen, K.E., Lindner, S.E., Shi, L., Shears, M.J., Harupa, A., Hopp, C.S., Vaughan, A.M., Springer, T.A., Moritz, R.L., Kappe, S.H.I., Sinnis, P.: Interrogating the Plasmodium Sporozoite Surface: Identification of Surface-Exposed Proteins and Demonstration of Glycosylation on CSP and TRAP by Mass Spectrometry-Based Proteomics. PLOS Pathogens. 12, e1005606 (2016). https://doi.org/10.1371/journal.ppat.1005606
7. Oludada, O.E., Costa, G., Burn Aschner, C., Obraztsova, A.S., Prieto, K., Canetta, C., Hoffman, S.L., Kremsner, P.G., Mordmüller, B., Murugan, R., Julien, J., Levashina, E.A., Wardemann, H.: Molecular and functional

properties of human Plasmodium falciparum CSP C-terminus antibodies. EMBO Mol Med. 15, EMMM202317454 (2023). https://doi.org/10.15252/emmm.202317454
8. Ngulube, P.: Humoral Immune Responses to P. falciparum Circumsporozoite Protein (Pfcsp) Induced by the RTS, S Vaccine – Current Update. Infection and Drug Resistance. 16, 2147–2157 (2023). https://doi.org/10.2147/IDR.S401247
9. Kpaka, J.N.: Selection Dynamics Of Circumsporozoite Protein (Csp) Vaccine Target In Ghana: The Contribution Of Human Leukocyte Antigen (Hla) Variation, http://ugspace.ug.edu.gh:8080/handle/123456789/41283, (2021)
10. Almeida, M.E.M. de, Vasconcelos, M.G.S. de, Tarragô, A.M., Mariúba, L.A.M.: Circumsporozoite Surface Protein-based malaria vaccines: a review. Rev. Inst. Med. trop. S. Paulo. 63, e11 (2021). https://doi.org/10.1590/S1678-9946202163011
11. Rts, T., Partnership (2014), S.C.T.: Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites. PLOS Medicine. 11, e1001685 (2014). https://doi.org/10.1371/journal.pmed.1001685
12. Alum, E.U., Ainebyoona, C., Egwu, C.O., Onohuean, H., Ugwu, O.P.-C., Uti, D.E., Alum, B.N., Echegu, D.A.: Mitigation of Malaria in Sub-Saharan Africa through Vaccination: A Budding Road Map for Global Malaria Eradication. Ethiopian Journal of Health Sciences. 35, (2025). https://doi.org/10.4314/ejhs.v35i3.9
13. Reeder, S.M., Bah, M.A., Tursi, N.J., Brooks, R.C., Patel, A., Esquivel, R., Eaton, A., Jhun, H., Chu, J., Kim, K., Xu, Z., Zavala, F., Weiner, D.B.: Strategic Variants of CSP Delivered as SynDNA Vaccines Demonstrate Heterogeneity of Immunogenicity and Protection from Plasmodium Infection in a Murine Model. Infection and Immunity. 89, (2021). https://doi.org/10.1128/iai.00728-20
14. Sherrard-Smith, E., Sala, K.A., Betancourt, M., Upton, L.M., Angrisano, F., Morin, M.J., Ghani, A.C., Churcher, T.S., Blagborough, A.M.: Synergy in anti-malarial pre-erythrocytic and transmission-blocking antibodies is achieved by reducing parasite density. eLife. 7, e35213 (2018). https://doi.org/10.7554/eLife.35213
15. Ngulube, P.: Humoral Immune Responses to P. falciparum Circumsporozoite Protein (Pfcsp) Induced by the RTS, S Vaccine – Current Update. Infection and Drug Resistance. 16, 2147–2157 (2023). https://doi.org/10.2147/IDR.S401247
16. MAHMOUDI, S., KESHAVARZ, H.: Malaria Vaccine Development: The Need for Novel Approaches: A Review Article. Iran J Parasitol. 13, 1–10 (2018)
17. Poespoprodjo, J.R., Douglas, N.M., Ansong, D., Kho, S., Anstey, N.M.: Malaria. The Lancet. 402, 2328–2345 (2023). https://doi.org/10.1016/S0140-6736(23)01249-7
18. Lo, E., Nguyen, K., Nguyen, J., Hemming-Schroeder, E., Xu, J., Etemesi, H., Githeko, A., Yan, G.: Plasmodium malariae Prevalence and csp Gene Diversity, Kenya, 2014 and 2015. Emerg Infect Dis. 23, 601–610 (2017). https://doi.org/10.3201/eid2304.161245
19. Võ, T.C., Lê, H.G., Kang, J.-M., Trinh, N.T.M., Van Khanh, C., Cho, M., Quang, H.H., Na, B.-K.: Genetic diversity and natural selection of circumsporozoite surface protein in Vietnam Plasmodium falciparum isolates. Malar J. 24, 320 (2025). https://doi.org/10.1186/s12936-025-05585-2
20. You, H., Jones, M.K., Gordon, C.A., Arganda, A.E., Cai, P., Al-Wassiti, H., Pouton, C.W., McManus, D.P.: The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections. Clinical Microbiology Reviews. 36, e00241-21 (2023). https://doi.org/10.1128/cmr.00241-21
21. Ahmed, R.: Advancements in mRNA Vaccine Technology: A Review of Applications in Infectious Disease Prevention. PJID. (2025). https://doi.org/10.70389/PJID.100004

CITE AS: Mutebi Mark (2026). Circumsporozoite Protein Biomarkers: Vaccine-Induced Immunity and Transmission Reduction in Endemic Settings. NEWPORT INTERNATIONAL JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 7(2):102-105.
https://doi.org/10.59298/NIJBAS/2026/7.2.102105